AUTHORS
Suchitra Acharya, MD, Murtadha Al-Khabori2, Runhui Wu, MD, PhD3, Priya Patel, PharmD4, Pascal Klaus, MD5, Pengling Sun, PhD6, Carrie Turich Taylor, PhD, MHS7, Sangeeta Raje, PhD8, Jasmine Healy, PhD9, Tina Hinnershitz10, Delphine Agathon, PhD11
AFFILIATIONS
1 Cohen Children’s Medical Center, Queens, New York, United States, Northwell Health, New Hyde Park, New York, United States
2 Sultan Qaboos University, Muscat, Oman
3 Haemophilia Comprehensive Care Center, Hematology Department, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China
4 Pfizer Inc., New York, New York, United States
5 Pfizer Pharma GmbH, Berlin, Germany
6 Pfizer Inc., Cambridge, Massachusetts, United States
7 Pfizer Inc., Collegeville, Pennsylvania, United States
8 Pfizer Inc., Collegeville, Pennsylvania, United States
9 Pfizer Canada ULC, Kirkland, Canada
10 Pfizer Inc., Collegeville, Pennsylvania, United States
11 Pfizer Inc., Paris, France
ABSTRACT
Background BASIS (NCT03938792) is an open-label, phase 3 trial of anti-tissue factor pathway inhibitor (TFPI) antibody marstacimab in male adult and adolescent participants (pts) 12–<75 years of age with severe hemophilia A (HA; factor VIII <1%) or moderately severe to severe hemophilia B (HB; factor IX ≤2%) with or without inhibitors. In pts with inhibitors, marstacimab met the primary efficacy endpoint, significantly reducing the annualized bleeding rate (ABR) of treated bleeds compared with prior on-demand (OD) bypassing agent therapy (n=48), with numerical reductions vs prior routine prophylaxis (RP; n=3). We report outcomes in the subgroup of adolescents with inhibitors in the BASIS trial.
Methods Pts with inhibitors completed a 6-month observational phase (OP) on RP or OD bypassing agent therapy before transitioning to the 12-month active treatment phase (ATP) where they received a single subcutaneous (SC) loading dose of 300 mg marstacimab followed by 150 mg once weekly (QW). After Day 180, pts meeting prespecified dose escalation criteria (weight ≥50 kg, ≥2 spontaneous bleeds requiring treatment in 6 months) could increase their dose to 300 mg QW. Efficacy assessments included ABR of treated bleeds and specific bleed types. Safety (including incidence and severity of adverse events [AEs] and immunogenicity) and pharmacokinetic (PK)/pharmacodynamic (PD) parameters were also assessed.
Results As of study completion (April 29, 2025), 16 adolescents (median age, 14.5 years [range, 12–17]; median weight, 51.7 kg [range, 25.9–75.9]) with HA (n=11) or HB (n=5) with inhibitors entered the OP and received OD (n=15) or RP therapy (n=1). Two pts with HA discontinued during the OP due to protocol deviations; 1 pt with HB entered the ATP but did not receive marstacimab due to failure to meet criteria identified after randomization. Adolescents (n=13 who received marstacimab) were enrolled from a globally diverse population with representation from Asia (46.2%), Europe (23.1%), Middle East (15.4%), and North America (15.4%); with most pts from China (38.5%). At OP baseline, 11 (84.6%) pts had ≥1 target joint, and 12 (92.3%) reported ≥6 bleeds in the last 6 months prior to study entry. In adolescents included in the efficacy analysis (n=12 with prior OD), mean ABR of treated bleeds was numerically lower with marstacimab in the ATP vs OD therapy in the OP (0.82 vs 27.66). The median ABR of treated bleeds in the ATP was 0.00. Mean ABR during the ATP was 0.82 for joint bleeds, 0.74 for spontaneous bleeds, 0.66 for target joint bleeds, and 1.92 for total (treated/untreated) bleeds. During the ATP, 9 of 12 (75%) adolescents had zero treated bleeds. The 1 adolescent receiving prior RP had 2 treated bleeding events during the OP and 0 treated bleeding events during the ATP. In all, 21 AEs were reported in 8 of 16 (50%) adolescents during the OP vs 35 AEs in 10 of 13 (76.9%) adolescents during the ATP. The majority of AEs in the ATP (in 9 of 10 [90%] adolescents) were grade 1. Two pts reported treatment-related AEs of fibrin D-dimer increased. No serious AEs were reported during the ATP. There were no temporary or permanent discontinuations due to AEs. No adolescents dose-escalated during the ATP. Antidrug antibodies, transient, developed in 1/13 adolescents (prior OD); they were not positive for neutralizing antibodies. Marstacimab steady-state plasma concentrations were ~1.1- to 2.2-fold higher in adolescents (150 mg SC QW; median range: 19,000–24,000 ng/mL) vs adults (150 mg SC QW; median range: 11,000–17,000 ng/mL). The higher concentrations in adolescents vs adults were attributed to weight differences in the populations. In general, no clinically relevant differences were seen in steady-state median ranges of PD endpoints following 150 mg QW marstacimab in adolescents vs adults: peak thrombin, 32–52 nM (n=13) vs 49–70 nM (n=34); prothrombin fragment 1+2, 590–867 pmoL/L (n=10) vs 523–690 pmoL/L (n=23); D-dimer, 0.3–0.4 μg/mL (n=13) vs 0.3 μg/mL (n=34); total TFPI, 360–469 (n=13) vs 251–293 ng/mL (n=34).
Conclusion Compared with previous OD bypassing agent therapy, SC QW marstacimab reduced bleeding in adolescents with HA or HB with inhibitors in the BASIS trial and was generally safe and well tolerated. Efficacy was consistent across age, hemophilia type, race, and region. No clinically relevant differences in PD endpoints were observed compared with adults; PK differences were explained by weight.
DISCLOSURES
Suchitra Acharya, MD: Pfizer, Sanofi, and Hemabiologics - Honoraria